Announcing Earth Day Plus (Apr 22 to May 3) – VC-Founder Matchup + Live Sessions. Learn More

Packaging of our DNA into chromatin is critical for dictating which parts of the genome can be transcribed and which cannot. TippingPoint Biosciences is the first company to tackle the core problem of targeting and drugging only the defectively packaged regions of the cancer genome, without affecting other correctly packaged regions. The TippingPoint platform leverages the latest advances in condensate biology and advanced screening tools to generate small molecule hits that can specifically modulate disease chromatin networks in a test tube, providing a new class of small molecules to treat disease. As many hard-to-treat diseases are a result of aberrant chromatin, TippingPoint’s platform will be expanded to create next-generation therapies across oncology and neurodegenerative diseases, starting with DIPG, a rare and lethal pediatric cancer.